Cytokinetics, Incorporated (CYTK) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in South San Francisco, CA, United States. The current CEO is Robert I. Blum.
CYTK has IPO date of 2004-04-30, 498 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $8.17B.
Cytokinetics, Incorporated is a late-stage biopharmaceutical company dedicated to discovering, developing, and commercializing small molecule drugs that modulate muscle function and contractility to treat debilitating diseases. The company's pipeline includes omecamtiv mecarbil, a cardiac myosin activator in Phase III trials for heart failure, and reldesemtiv, a skeletal muscle troponin activator in Phase III development for amyotrophic lateral sclerosis and spinal muscular atrophy. Additional candidates in development include aficamten, a cardiac myosin inhibitor in Phase III trials for obstructive hypertrophic cardiomyopathy, alongside earlier-stage programs such as CK-136 and CK-3772271. Founded in 1997 and headquartered in South San Francisco, California, Cytokinetics maintains a strategic alliance with Astellas Pharma Inc. to advance its muscle-focused therapeutic platform.
